Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Osivax Belgique is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and a distinct art unit. The company's current interaction with the patent office is focused on this one specific matter. This narrow scope of activity indicates that the company's intellectual property efforts are currently concentrated on a single technical development within the biotechnology field.
The busiest examiner, KINSEY WHITE, NICOLE ERIN, is managing 1 pending office action. This represents the total number of pending office actions for the company. Because there is a distinct examiner and a distinct art unit, the company's current patent office activity is highly centralized. This structure allows for a very specific and focused prosecution strategy for the company's pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686381 | IMMUNOGENIC COMPOSITIONS AND THEIR USE | KINSEY WHITE, NICOLE ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686381 | IMMUNOGENIC COMPOSITIONS AND THEIR USE | KINSEY WHITE, NICOLE ERIN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686381 | IMMUNOGENIC COMPOSITIONS AND THEIR USE | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOsivax Belgique has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nicole Erin Kinsey White has the most, with 1 of Osivax Belgique's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
